AAAAAA

   
Results: 1-10 |
Results: 10
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23
Authors: Fisher, B Anderson, S Tan-Chiu, E Wolmark, N Wickerham, DL Fisher, ER Dimitrov, NV Atkins, JN Abramson, N Merajver, S Romond, EH Kardinal, CG Shibata, HR Margolese, RG Farrar, WB
Citation: B. Fisher et al., Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23, J CL ONCOL, 19(4), 2001, pp. 931-942
Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer
Authors: Abdessalam, SF Zervos, EE Prasad, M Farrar, WB Yee, LD Walker, MJ Carson, WB Burak, WE
Citation: Sf. Abdessalam et al., Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer, AM J SURG, 182(4), 2001, pp. 316-320
Selective analysis of the sentinel node in breast cancer
Authors: Zervos, EE Badgwell, BD Abdessalam, SF Farrar, WB Walker, MJ Yee, LD Burak, WE
Citation: Ee. Zervos et al., Selective analysis of the sentinel node in breast cancer, AM J SURG, 182(4), 2001, pp. 372-376
NCCN Practice Guidelines for breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, CE Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS McCormick, B Nabell, LM Reed, EC Silver, SM Smith, ML Somlo, G Theriault, R Ward, JH Winer, EP Wolff, A
Citation: Rw. Carlson et al., NCCN Practice Guidelines for breast cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 33-49
Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients
Authors: Saha, S Farrar, WB Young, DC Ferrara, JJ Burak, WE
Citation: S. Saha et al., Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients, J SURG ONC, 73(3), 2000, pp. 134-137
Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer
Authors: Harris, RE Kasbari, S Farrar, WB
Citation: Re. Harris et al., Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer, ONCOL REP, 6(1), 1999, pp. 71-73
Update: NCCN practice guidelines for the treatment of breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, C Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS Mccormick, B Nabell, LM Reed, EC Silver, SM Smith, MLP Somlo, G Theriault, RL Winer, EP
Citation: Rw. Carlson et al., Update: NCCN practice guidelines for the treatment of breast cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 187-212
Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer
Authors: Harris, RE Robertson, FM Abou-Issa, HM Farrar, WB Brueggemeier, R
Citation: Re. Harris et al., Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer, MED HYPOTH, 52(4), 1999, pp. 291-292
Routine preoperative lymphoscintigraphy is not necessary prior to sentinelnode biopsy for breast cancer
Authors: Burak, WE Walker, MJ Yee, LD Kim, JA Saha, S Hinkle, G Olsen, JO Pozderac, R Farrar, WB
Citation: We. Burak et al., Routine preoperative lymphoscintigraphy is not necessary prior to sentinelnode biopsy for breast cancer, AM J SURG, 177(6), 1999, pp. 445-449
Neoplasms of the appendix
Authors: Burak, WE Farrar, WB
Citation: We. Burak et Wb. Farrar, Neoplasms of the appendix, CANCER SURGERY FOR THE GENERAL SURGEON, 1999, pp. 257-263
Risultati: 1-10 |